Enfusion (ENFN) Stock Price, News & Analysis $9.75 +0.09 (+0.93%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$9.52▼$9.8850-Day Range$7.87▼$10.2352-Week Range$7.37▼$12.31Volume200,375 shsAverage Volume278,801 shsMarket Capitalization$1.24 billionP/E Ratio121.89Dividend YieldN/APrice Target$10.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Enfusion MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside4.3% Upside$10.17 Price TargetShort InterestHealthy4.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.66Based on 2 Articles This WeekInsider TradingSelling Shares$11.51 M Sold Last QuarterProj. Earnings Growth100.00%From $0.09 to $0.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsComputer And Technology Sector401st out of 583 stocksPrepackaged Software Industry128th out of 193 stocks 1.0 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.17, Enfusion has a forecasted upside of 4.3% from its current price of $9.75.Amount of Analyst CoverageEnfusion has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.17% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Enfusion has recently decreased by 12.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 0.7 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Enfusion this week, compared to 1 article on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,514,150.00 in company stock.Percentage Held by Insiders39.18% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.43% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 100.00% in the coming year, from $0.09 to $0.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 121.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 109.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 121.89, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 231.14.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 10.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enfusion Stock (NYSE:ENFN)Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesDecember 7, 2023 | americanbankingnews.comOleg Movchan Sells 150,000 Shares of Enfusion, Inc. (NYSE:ENFN) StockDecember 2, 2023 | americanbankingnews.comEnfusion, Inc. (NYSE:ENFN) Given Consensus Recommendation of "Hold" by BrokeragesDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 30, 2023 | americanbankingnews.comStephen Malherbe Sells 1,000,000 Shares of Enfusion, Inc. (NYSE:ENFN) StockNovember 20, 2023 | markets.businessinsider.comEnfusion Names Neal Pawar COO - Quick FactsNovember 20, 2023 | finance.yahoo.comEnfusion Announces Appointment of Chief Operating OfficerNovember 12, 2023 | finance.yahoo.comEnfusion, Inc. (NYSE:ENFN) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | finance.yahoo.comEarnings Miss: Enfusion, Inc. Missed EPS By 31% And Analysts Are Revising Their ForecastsDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 10, 2023 | finance.yahoo.comEnfusion, Inc.'s (NYSE:ENFN) Stock Is Going Strong: Have Financials A Role To Play?November 9, 2023 | morningstar.comEnfusion Inc Class A ENFNNovember 8, 2023 | seekingalpha.comEnfusion: Still Bullish Considering Q3 EBITDA BeatNovember 7, 2023 | markets.businessinsider.comEnfusion Adds 9% After Q3 Revenue Beats EstimatesNovember 7, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Reports Q3 Earnings: What Key Metrics Have to SayNovember 7, 2023 | finance.yahoo.comEnfusion Announces Third Quarter 2023 ResultsOctober 31, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOctober 31, 2023 | finanznachrichten.deEnfusion, Inc.: Enfusion Announces Date of Third Quarter 2023 ResultsOctober 24, 2023 | finance.yahoo.comIs It Time To Consider Buying Enfusion, Inc. (NYSE:ENFN)?October 19, 2023 | finance.yahoo.comEnfusion Announces Date of Third Quarter 2023 ResultsOctober 10, 2023 | finance.yahoo.comEnfusion Launches Portfolio Workbench, Empowering Portfolio Managers to Seamlessly Rebalance Multi-Asset PortfoliosSeptember 28, 2023 | finanznachrichten.deEnfusion, Inc.: Enfusion Announces Closing of New $100 Million Credit FacilitySeptember 20, 2023 | finance.yahoo.comIs Enfusion, Inc. (NYSE:ENFN) Trading At A 30% Discount?September 18, 2023 | finance.yahoo.comEnfusion Announces Closing of New $100 Million Credit FacilitySeptember 3, 2023 | fool.comEnfusion (NYSE: ENFN)August 24, 2023 | seekingalpha.comEnfusion Faces Cross-Currents In Investment Management Software MarketAugust 16, 2023 | barrons.comEnfusion Inc.August 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Enfusion (ENFN) and Wolfspeed (WOLF)See More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Prepackaged software Sub-IndustryN/A SectorComputer and Technology Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,006Year FoundedN/APrice Target and Rating Average Stock Price Target$10.17 High Stock Price Target$12.00 Low Stock Price Target$9.00 Potential Upside/Downside+4.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio121.89 Forward P/E Ratio108.33 P/E Growth2.28Net Income$-7,650,000.00 Net Margins3.67% Pretax Margin6.23% Return on Equity9.13% Return on Assets7.20% Debt Debt-to-Equity RatioN/A Current Ratio3.79 Quick Ratio3.79 Sales & Book Value Annual Sales$150.35 million Price / Sales8.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book10.71Miscellaneous Outstanding Shares127,480,000Free Float77,532,000Market Cap$1.24 billion OptionableNot Optionable Beta1.02 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 48)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 52)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 50)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMr. Neal PawarChief Operating OfficerMr. Daniel Groman (Age 34)Chief Technology Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMatt CampobassoGeneral CounselCaroline MaHead of Corporate DevelopmentMr. Joseph DefeoGlobal Head of Managed Services ProductionMore ExecutivesKey CompetitorsHello GroupNASDAQ:MOMOZuoraNYSE:ZUOVTEXNYSE:VTEXAvid TechnologyNASDAQ:AVIDTuyaNYSE:TUYAView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 105,236 shares on 12/7/2023Ownership: 0.361%Citigroup Inc.Sold 8,183 shares on 12/6/2023Ownership: 0.002%Oleg MovchanSold 150,000 sharesTotal: $1.51 M ($10.09/share)Stephen MalherbeSold 1,000,000 sharesTotal: $9.86 M ($9.86/share)AQR Capital Management LLCBought 15,669 shares on 11/15/2023Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions ENFN Stock Analysis - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price target for 2024? 6 brokers have issued 12 month price objectives for Enfusion's shares. Their ENFN share price targets range from $9.00 to $12.00. On average, they expect the company's share price to reach $10.17 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2023? Enfusion's stock was trading at $9.67 at the beginning of 2023. Since then, ENFN stock has increased by 0.8% and is now trading at $9.75. View the best growth stocks for 2023 here. Are investors shorting Enfusion? Enfusion saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,910,000 shares, a drop of 12.8% from the October 31st total of 2,190,000 shares. Based on an average trading volume of 318,800 shares, the short-interest ratio is presently 6.0 days. Currently, 4.2% of the company's stock are short sold. View Enfusion's Short Interest. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our ENFN earnings forecast. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings results on Tuesday, November, 7th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.01. The company earned $44.36 million during the quarter, compared to analyst estimates of $43.95 million. Enfusion had a trailing twelve-month return on equity of 9.13% and a net margin of 3.67%. When did Enfusion IPO? (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include New York State Common Retirement Fund (1.31%), Hudson Bay Capital Management LP (0.36%), Northern Trust Corp (0.27%), Charles Schwab Investment Management Inc. (0.23%), Bank of New York Mellon Corp (0.10%) and AQR Capital Management LLC (0.07%). Insiders that own company stock include Bronwen Bastone, Dan Groman, Hillhouse Investment Managemen, Oleg Movchan, Roy Luo, Stephen Malherbe and Tarek Hammoud. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:ENFN) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.